Section Arrow
PMCB.NASDAQ
- PharmaCyte Biotech
(Financial Status)
Quotes are at least 15-min delayed:2026/08/31 17:09 EDT
After Hours
Last
 0.5009
0 (0.00%)
Bid
0.5
Ask
0.53
High 0.5009 
Low 0.5009 
Volume
Regular Hours (Closed)
Last
 0.5009
-0.0141 (-2.74%)
Day High 
0.529799 
Prev. Close
0.515 
1-M High
0.62 
Volume 
105.52K 
Bid
0.5
Ask
0.53
Day Low
0.48 
Open
0.52 
1-M Low
0.5043 
Market Cap 
5.53M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.53 
20-SMA 0.55 
50-SMA 0.63 
52-W High 1.51 
52-W Low 0.5043 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.77/-0.38
Enterprise Value
5.53M
Balance Sheet
Book Value Per Share
3.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CLGNCollPlant Biotechnologies Ltd0.3879+0.0299+8.35%-- 
After Hours 0.3641 -0.0238 -6.14%
AIMAIM ImmunoTech Inc.0.226-0.0324-12.54%-- 
After Hours 0.23169 +0.00569 +2.52%
ROIVRoivant Sciences Ltd34.64-0.07-0.20%-- 
After Hours 35.8942 +1.2542 +3.62%
CVKDCadrenal Therapeutics Inc1.75+0.21+13.64%-- 
After Hours 1.6 -0.15 -8.57%
MRNAModerna140.34+2.35+1.70%-- 
After Hours 139.0767 -1.2633 -0.90%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.